Akebia Therapeutics Sees 55% Vafseo Revenue Growth in Q2 2025, Analysts Predict 145% Upside Potential

Akebia Therapeutics (AKBA) reported a 55% increase in Vafseo revenue for Q2, reaching $13 million. Analysts set an average price target of $7.40, implying a 145.85% potential upside. GuruFocus estimates a GF Value of $1.16, indicating a potential downside of 61.46%. The company projects expanding access to reach 75,000 patients by September and anticipates a further outreach to 275,000 patients by the fourth quarter.

Akebia Therapeutics, Inc. (Nasdaq: AKBA) has reported robust financial results for the second quarter of 2025, highlighting significant growth in its Vafseo® (vadadustat) revenue. The company's net product revenues from Vafseo reached $13.3 million, marking a 55% increase from the first quarter of 2025. This substantial growth is attributed to the expanding prescription demand and the operationalization of Vafseo in dialysis clinics across the United States [1].

The company's total net product revenues for the second quarter of 2025 stood at $60.5 million, an increase of 43.3% year-over-year, driven primarily by the strong performance of Vafseo. Akebia's Chief Executive Officer, John P. Butler, expressed optimism about the therapy's potential, stating that the company is working to increase utilization at mid-sized dialysis organizations and expects to operationalize protocols with both Dialysis Clinics, Inc. (DCI) and Innovative Renal Care (IRC) by September [1].

DaVita, a leading dialysis organization serving more than 200,000 patients, has begun ordering Vafseo to support an operational pilot in the third quarter of 2025. This pilot aims to ensure that prescribers can efficiently deliver the drug to dialysis patients, potentially leading to broader prescribing before the end of the year. The company expects to reach 75,000 patients by September, expanding access to more than 275,000 patients by the fourth quarter of 2025 [1].

Akebia's financial results also include a $47.2 million net product revenue from Auryxia® (ferric citrate), despite the loss of exclusivity in March 2025. The company's total revenues for the second quarter of 2025 reached $62.5 million, a 43.3% increase compared to the same period in 2024. The increase was driven by the launch of Vafseo in January 2025 and the growth in Auryxia sales [1].

Analysts have set an average price target of $7.40 for Akebia, implying a potential 145.85% upside. GuruFocus estimates a GF Value of $1.16, indicating a potential downside of 61.46%. The company's strong financial performance and the potential for further expansion in patient access to Vafseo are likely contributing factors to these valuation metrics [2].

Akebia is also making progress in its post-marketing development strategy, with ongoing clinical trials and plans to initiate a Phase 3 clinical trial to study the use of vadadustat for treating anemia in late-stage CKD patients not on dialysis by the end of 2025. The company has requested a Type-C meeting with the U.S. Food and Drug Administration to discuss these developments [1].

In conclusion, Akebia Therapeutics' strong Q2 2025 financial performance, driven by the growth of Vafseo, highlights the company's potential to become a leader in the treatment of anemia in patients with chronic kidney disease. The company's strategic initiatives and ongoing clinical trials position it well for future growth and expansion.

References:
[1] https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-reports-second-quarter-2025-financial
[2] GuruFocus - Akebia Therapeutics, Inc. (AKBA)